Expression profiling of IDH-mutant low-grade gliomas treated with TMZ identified a three-lncRNA signature (including HOXD-AS2 and H19-related lncRNAs) that is correlated with TMZ resistance and progression-free survival [22,62,64]. This evidence concerns the gene IDH1 and glioma.